Stocks
Delcath Systems, Inc.DCTH
NASDAQHealthcareBiotechnology$9.45-0.32%
Price as of · delayed, not real-time
Specializing in interventional oncology, this company develops proprietary systems for targeted drug delivery to treat liver cancers. Its flagship product, the Hepatic Delivery System, combines chemotherapy with filtration to reduce systemic toxicity. Investors monitor its progress due to the high unmet need in liver cancer treatments and its novel approach to localized therapy.
Market Cap: $328.4M52W Range: $8.12 – $18.23
Congressional Interest in Delcath Systems, Inc. (DCTH)
1 member of Congress has disclosed 1 trade in Delcath Systems, Inc. (DCTH), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading DCTH?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-06-09 | Roger W. Marshall | sell | $1K – $15K |